|
 |
|
|||||||
|
|||||||||
© 2005 by the American Diabetes Association, Inc.
Epidemiology/Health Services/Psychosocial Research |
Availability of Inhaled Insulin Promotes Greater Perceived Acceptance of Insulin Therapy in Patients With Type 2 Diabetes
1 Department of Primary Care & General Practice, University of Birmingham, Birmingham, U.K.
2 Ochsner Clinic Foundation, New Orleans, Louisiana
3 Société Française de Médecine Générale, Issy les Moulineaux, France
4 Profil Institute for Clinical Research, Chula Vista, California
5 Department of Primary Health Care, Göteborg University, Göteborg, Sweden
6 Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
7 Aventis Pharma, Bridgewater, New Jersey
8 Pfizer, Karlsruhe, Germany
Address correspondence and reprint requests to Nick Freemantle, PhD, Professor of Clinical Epidemiology & Biostatistics, Department of Primary Care and General Practice, Primary Care Clinical Sciences Building, University of Birmingham Edgbaston, Birmingham B15 2TT U.K. E-mail: n.freemantle@bham.ac.uk
Abbreviations: INH, inhaled insulin • OAD, oral antidiabetic agent
| The first 20% of the full text of this article appears below. |
 |
INTRODUCTION |
|---|
Inhaled insulin (INH, Exubera) is under investigation for preprandial treatment of patients with type 1 and type 2 diabetes (1–3). This dry-powder insulin formulation is delivered by aerosol, permitting the noninvasive administration of rapid-acting insulin (4). Preliminary studies have shown that INH provides reproducible and effective control of glycemia (1,5–7). This randomized controlled trial examined the extent to which the availability of INH affects the perceived acceptability of insulin therapy among patients with type 2 diabetes who failed to achieve target glycemia on current therapy.
|
RESEARCH DESIGN AND METHODS |
|---|
Male or female participants (n = 779) aged 35–80 years with at least 3 months duration of type 2 diabetes and a HbA1c >8%, despite current therapy, were recruited from seven countries. Permitted current therapy included dietary measures and/or oral antidiabetic agents (OADs). Patients receiving insulin injections, smokers, or those who had significant pulmonary diseases were excluded. All patients gave informed consent, and local research ethics review boards approved the study.
Participants were randomly assigned to receive either educational information about the potential risks and benefits of all currently licensed treatment options only (OADs and/or subcutaneous insulin, n = 388) or information about the potential risks and benefits of
|
RESULTS |
|---|
|
CONCLUSIONS |
|---|
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. J Bailey, C. Day, and A. H Barnett Exubera expires The British Journal of Diabetes & Vascular Disease, November 1, 2007; 7(6): 255 - 256. [PDF]
|
|
|
|
 |
|
 J. S. Skyler, L. Jovanovic, S. Klioze, J. Reis, W. Duggan, and for the Inhaled Human Insulin Type 1 Diabetes Stud Two-Year Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 1 Diabetes Diabetes Care, March 1, 2007; 30(3): 579 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghosh and A. Collier Inhaled insulins Postgrad. Med. J., March 1, 2007; 83(977): 178 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Peragallo-Dittko Removing Barriers to Insulin Therapy The Diabetes Educator, March 1, 2007; 33(Supplement_3): 60S - 65S. [Full Text] [PDF]
|
|
|
|
 |
|
 G. T. McMahon and R. A. Arky Inhaled Insulin for Diabetes Mellitus N. Engl. J. Med., February 1, 2007; 356(5): 497 - 502. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ceglia, J. Lau, and A. G. Pittas Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med, November 7, 2006; 145(9): 665 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bellary and A. H Barnett Review: Inhaled insulin: overcoming barriers to insulin therapy? The British Journal of Diabetes & Vascular Disease, May 1, 2006; 6(3): 103 - 108. [Abstract] [PDF]
|
|
|
|
|
|
R. P. Hayes, L. Bowman, P. O. Monahan, D. G. Marrero, and C. A. McHorney Understanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordance. The Diabetes Educator, May 1, 2006; 32(3): 404 - 414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rosenstock, B. Zinman, L. J. Murphy, S. C. Clement, P. Moore, C. K. Bowering, R. Hendler, S.-P. Lan, and W. T. Cefalu Efficacy and Safety of Inhaled Insulin Therapy Ann Intern Med, April 4, 2006; 144(7): 533 - 534. [Full Text] [PDF]
|
|
|
|
|
|
R. H.A. Becker, S. Sha, A. D. Frick, and R. J. Fountaine The Effect of Smoking Cessation and Subsequent Resumption on Absorption of Inhaled Insulin Diabetes Care, February 1, 2006; 29(2): 277 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rosenstock, B. Zinman, L. J. Murphy, S. C. Clement, P. Moore, C. K. Bowering, R. Hendler, S.-P. Lan, and W. T. Cefalu Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes: A Randomized, Controlled Trial Ann Intern Med, October 18, 2005; 143(8): 549 - 558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Comi Treatment of Type 2 Diabetes Mellitus: A Weighty Enigma Ann Intern Med, October 18, 2005; 143(8): 609 - 610. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |